Illinois Municipal Retirement Fund Buys 25,585 Shares of Elanco Animal Health Incorporated $ELAN

Illinois Municipal Retirement Fund lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 49.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,279 shares of the company’s stock after buying an additional 25,585 shares during the period. Illinois Municipal Retirement Fund’s holdings in Elanco Animal Health were worth $1,849,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ELAN. Peak Retirement Planning Inc. bought a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $2,756,000. Norges Bank bought a new stake in Elanco Animal Health in the fourth quarter valued at $32,415,000. Robeco Institutional Asset Management B.V. purchased a new position in Elanco Animal Health during the 4th quarter valued at $3,947,000. BNP Paribas Financial Markets increased its position in Elanco Animal Health by 3,682.0% during the 4th quarter. BNP Paribas Financial Markets now owns 2,252,961 shares of the company’s stock valued at $50,985,000 after purchasing an additional 2,193,391 shares during the period. Finally, Hardman Johnston Global Advisors LLC bought a new position in Elanco Animal Health in the 4th quarter worth $14,276,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 2.5%

Shares of NYSE ELAN opened at $25.18 on Tuesday. The firm’s 50 day moving average price is $23.70 and its 200-day moving average price is $23.91. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a market cap of $12.57 billion, a PE ratio of -50.35, a P/E/G ratio of 1.69 and a beta of 1.68.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter last year, the firm earned $0.37 earnings per share. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lifted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.55.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.